Molecular Partners AG
MOLN
Pozycja w akcjach
#19819
Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to... Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market novel therapeutic proteins. Leveraging its proprietary DARPin® platform, the company is advancing a diverse pipeline of product candidates. Key among these is Abicipar, a DARPin-based treatment currently in Phase III clinical development for significant ophthalmic conditions like neovascular wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Additionally, their portfolio features multi-specific DARPin candidates targeting infectious diseases, such as MP0420 and MP0423, both designed to combat the SARS-CoV-2 virus (COVID-19). In the oncology space, Molecular Partners is advancing several programs: MP0310, in Phase Ia for immuno-oncology; MP0317, a Phase I tumor-localized immune agonist engineered to activate immune cells within tumors; and MP0274, also in Phase I, aimed at HER2-positive cancers. Further early-stage assets include MP0533, a CD3 T cell candidate for acute myeloid leukemia, and MP0250, which targets vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and human serum albumin (HSA) to enhance therapeutic half-life. The company actively collaborates with leading pharmaceutical companies. Notable alliances include a partnership with Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; agreements with Amgen SA and Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc. They also maintain relationships with various other third-party collaborators. Established in 2004, Molecular Partners AG is headquartered in Schlieren, Switzerland.
Cena akcji
$3.69
Kapitalizacja rynkowa
$141.31M
Zmiana (1 dzień)
-7.00%
Zmiana (1 rok)
3.11%
Kraj
CH
Handel Molecular Partners AG (MOLN)
Kategoria
Healthcare
Liczba akcji w obrocie dla Molecular Partners AG (MOLN)
Liczba akcji w obrocie na dzień October 2026: 0
Zgodnie z najnowszymi raportami finansowymi i ceną akcji Molecular Partners AG, aktualna liczba akcji w obrocie to 0. Na koniec October 2026 firma posiadała 0 akcji w obrocie. Liczba akcji w obrocie jest zwykle kształtowana przez podziały akcji i skupy akcji.
Historia liczby akcji w obrocie dla Molecular Partners AG (MOLN) od 2026 do 2026
Akcje w obrocie na koniec każdego roku
| Rok | Akcje w obrocie | Zmień |
|---|---|---|
| Za mało danych dla podanych dat. | ||
Akcje w obrocie dla podobnych firm lub konkurentów
| Firma | Akcje w obrocie | Różnica | Kraj |
|---|---|---|---|
| 253.90M | - |
US
|
|
| 396.00M | - |
US
|
|
| 478.91M | - |
AU
|
|
| 62.19M | - |
NL
|
|
| - | - |
CH
|
